Avadel Pharmaceuticals Plc Stock Filter Stocks by Fundamentals
| AVDL Stock | USD 11.22 0.44 3.77% |
Avadel Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Avadel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Avadel Stock. The fundamental analysis module provides a way to measure Avadel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avadel Pharmaceuticals stock.
Avadel | Shares Owned by Institutions |
Avadel Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avadel Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avadel Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Avadel Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Avadel Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Avadel Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Avadel Pharmaceuticals' value.| Shares | Tri Locum Partners Lp | 2024-09-30 | 1.7 M | Woodline Partners Lp | 2024-06-30 | 1.5 M | Brandes Investment Partners & Co | 2024-09-30 | 1.4 M | Tang Capital Management Llc | 2024-09-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.1 M | Checkpoint Capital Lp | 2024-09-30 | 1.1 M | Adage Capital Partners Gp Llc | 2024-06-30 | 994.7 K | Samsara Biocapital, Llc | 2024-09-30 | 967.5 K | Hhg Plc | 2024-06-30 | 13.3 M | Polar Capital Holdings Plc | 2024-06-30 | 6.6 M |
Avadel Fundamentals
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 96.27 M | ||||
| Shares Owned By Insiders | 4.77 % | ||||
| Shares Owned By Institutions | 80.00 % | ||||
| Number Of Shares Shorted | 9.45 M | ||||
| Price To Earning | 61.46 X | ||||
| Price To Book | 14.48 X | ||||
| Price To Sales | 7.83 X | ||||
| Revenue | 27.96 M | ||||
| Gross Profit | 16.59 M | ||||
| EBITDA | (149.12 M) | ||||
| Net Income | (160.28 M) | ||||
| Cash And Equivalents | 104.12 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 35.38 M | ||||
| Debt To Equity | 2.63 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (128.51 M) | ||||
| Short Ratio | 12.45 X | ||||
| Earnings Per Share | (1.09) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 24.7 | ||||
| Number Of Employees | 154 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 1.27 B | ||||
| Total Asset | 164.7 M | ||||
| Retained Earnings | (745.5 M) | ||||
| Working Capital | 97.35 M | ||||
| Current Asset | 177.85 M | ||||
| Current Liabilities | 59.19 M | ||||
| Net Asset | 164.7 M |
About Avadel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avadel Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avadel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avadel Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Avadel Pharmaceuticals Piotroski F Score and Avadel Pharmaceuticals Altman Z Score analysis. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.